Pharma services M&A: Positive sentiment in a pioneering sector

These are the key takeaway from their conversation... 

• Market dynamics, including R&D spending, market complexity, investor appetite, and increasing multiples are influencing pharma services businesses and M&A activity 

• Deal activity is high in the mid-market, as niche players provide consolidation opportunities among international and private equity-backed buyers

• International buyer appetite is strong, and we've seen increased competition from the US, Asia, and India

• The recent tariff policy changes haven't had a major impact on pharma services because the focus is on goods 

• The UK is a centre of excellence; supported by an academic community driving innovation, and R&D tax incentives making the UK an attractive location to start a business

• Regulations are international, but the sector is adaptive and open to changes

• Client diversification is a key risk, especially given current economic conditions – broadening customer concentration and geographical footprint is key to reduce the risk 

• In advance of an exit businesses need to consider intellectual property protection, diversification, and focusing on international opportunities